Compare 3M Company (MMM) vs Novartis AG (NVS) Price & Performance

3M CompanyTrade

Novartis AGTrade

Price performance (Past 24H)

Key statistics

3M Company vs Novartis AG — how do they compare? 3M Company trades at $170.75 (market cap $82.99B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 3.5× 3M Company's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.

	MMM	NVS
Market Cap	$82.99B	$290.25B
Sector	Industrials	Health
52-Week High	$174.61	$168.62
52-Week Low	$141.10	$113.50
Enterprise Value	$91.39B	$330.27B
Dividend Yield	1.96%	3.17%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MMM

3M beats Q2 earnings and raises outlook, driven by growth in optics and industrial segments.Seeking Alpha · 4 hours agoBullish 3M shares jump 10% after beating Q2 earnings and raising full-year EPS forecastGordon Thompson · 5 hours agoBullish 3M shares jump 9% after Q2 earnings beat and raised 2026 guidanceProactive Investors · 10 hours agoBullish View details →

NVS

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.Gordon Thompson · 23 hours agoNeutral New report details 1,230+ bioinformatics deals, revealing market trends and deal structures through 2026Researchandmarkets.Com · 4 days agoNeutral FDA approves Fabhalta as first drug to significantly slow kidney decline in IgAN patientsNovartis · 4 days agoBullish View details →

About 3M Company

3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.

About Novartis AG

Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.